209 related articles for article (PubMed ID: 33421291)
1. Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action.
Noordermeer T; Molhoek JE; Schutgens REG; Sebastian SAE; Drost-Verhoef S; van Wesel ACW; de Groot PG; Meijers JCM; Urbanus RT
J Thromb Haemost; 2021 Apr; 19(4):1018-1028. PubMed ID: 33421291
[TBL] [Abstract][Full Text] [Related]
2. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C.
Noordermeer T; Chemlal S; Jansma JJ; van der Vegte V; Schutgens REG; Limper M; de Groot PG; Meijers JCM; Urbanus RT
J Thromb Haemost; 2023 Sep; 21(9):2509-2518. PubMed ID: 37290588
[TBL] [Abstract][Full Text] [Related]
3. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in patients with the 'antiphospholipid' syndrome: immunological specificity and clotting profiles.
Kandiah DA; Krilis SA
Lupus; 1998; 7(5):323-32. PubMed ID: 9696136
[TBL] [Abstract][Full Text] [Related]
4. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
[TBL] [Abstract][Full Text] [Related]
5. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids.
Takeya H; Mori T; Gabazza EC; Kuroda K; Deguchi H; Matsuura E; Ichikawa K; Koike T; Suzuki K
J Clin Invest; 1997 May; 99(9):2260-8. PubMed ID: 9151800
[TBL] [Abstract][Full Text] [Related]
6. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants.
Simmelink MJ; Derksen RH; Arnout J; De Groot PG
J Thromb Haemost; 2003 Apr; 1(4):740-7. PubMed ID: 12871410
[TBL] [Abstract][Full Text] [Related]
7. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces.
Arnout J; Wittevrongel C; Vanrusselt M; Hoylaerts M; Vermylen J
Thromb Haemost; 1998 Jan; 79(1):79-86. PubMed ID: 9459328
[TBL] [Abstract][Full Text] [Related]
8. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I.
Arnout J; Meijer P; Vermylen J
Thromb Haemost; 1999 Jun; 81(6):929-34. PubMed ID: 10404770
[TBL] [Abstract][Full Text] [Related]
9. Anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) increase the risk for thrombosis based on lupus anticoagulant positivity.
Zhang Y; Su Y; Guo H; Wang L; Li A; Wang C; Zhang J; Qiao R
Clin Biochem; 2023 Feb; 112():17-23. PubMed ID: 36535385
[TBL] [Abstract][Full Text] [Related]
10. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies.
Galli M; Finazzi G; Bevers EM; Barbui T
Blood; 1995 Jul; 86(2):617-23. PubMed ID: 7605991
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants.
Arnout J
Thromb Haemost; 2001 Jul; 86(1):83-91. PubMed ID: 11487046
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis.
Forastiero R; Martinuzzo M; Pombo G; Puente D; Rossi A; Celebrin L; Bonaccorso S; Aversa L
J Thromb Haemost; 2005 Jun; 3(6):1231-8. PubMed ID: 15946213
[TBL] [Abstract][Full Text] [Related]
13. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
Arnout J
Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C.
Galli M; Ruggeri L; Barbui T
Blood; 1998 Mar; 91(6):1999-2004. PubMed ID: 9490682
[TBL] [Abstract][Full Text] [Related]
15. The challenges of lupus anticoagulants.
Chighizola CB; Raschi E; Banzato A; Borghi MO; Pengo V; Meroni PL
Expert Rev Hematol; 2016; 9(4):389-400. PubMed ID: 26789237
[TBL] [Abstract][Full Text] [Related]
16. Double positivity of anti-β
Yun J; Gu J; Kim HK
J Thromb Thrombolysis; 2021 Nov; 52(4):1133-1136. PubMed ID: 33914240
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of beta2-glycoprotein I-dependent lupus anticoagulants.
Arnout J; Vermylen J
Lupus; 1998; 7 Suppl 2():S23-8. PubMed ID: 9814667
[TBL] [Abstract][Full Text] [Related]
18. Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity.
Cattini MG; Bison E; Pontara E; Cheng C; Denas G; Pengo V
J Thromb Haemost; 2020 May; 18(5):1124-1132. PubMed ID: 32052568
[TBL] [Abstract][Full Text] [Related]
19. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
[TBL] [Abstract][Full Text] [Related]
20. Both IgG and IgM anti-beta2 glycoprotein I antibodies assays are clinically useful to the antiphospholipid syndrome diagnosis.
Li R; Daguzan M; Vandermijnsbrugge F; Gyling M; Cantinieaux B
Acta Clin Belg; 2014 Dec; 69(6):433-8. PubMed ID: 25103595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
